# PubMed-like Abstract (Paraphrased)
Background: BRAF V600E variants in melanoma enable targeted inhibitors with measurable response rates.
Conclusion: Evidence supports targeted therapy pathways when BRAF V600E is present; monitoring for toxicity is recommended.
